After years of using machine learning to mine lab data and identify promising molecules, large drugmakers are now pushing generative AI into the most heavily regulated parts of drug development: clinical trials and regulatory submissions. New tools built on large language models (LLMs) are being deployed to help design study protocols, draft clinical trial documents, generate plain‑language patient summaries and assemble complex dossiers for agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Pharma executives say the goal is not to let AI make approval decisions, but to eliminate months of manual work that slows the path from early data to market approval. In an industry where bringing a single drug to patients can take a decade and cost billions of dollars, even incremental time savings can translate into major financial and public‑health gains.
Trial design, reporting and patient communication in AI’s sights
One of the most active areas is clinical trial design, where LLM‑based systems sift through historic protocols, outcomes and regulatory feedback to propose inclusion criteria, endpoints and statistical plans that are more likely to win agency acceptance on the first pass. Companies are also using AI to generate multiple protocol variants that can be rapidly compared for feasibility, cost and recruitment potential before a final design is chosen.
Once a study is running, AI tools are being tested to help draft interim and final clinical study reports, pulling structured data from trial databases and converting it into narrative sections that statisticians and medical writers then refine. In parallel, some drugmakers are piloting generative systems to produce patient‑friendly summaries of trial results, a growing requirement in Europe and other regions that want participants and the public to understand what studies found in clear, non‑technical language.
Automating the grind of regulatory submissions
Perhaps the most sensitive frontier is the use of AI to compile and cross‑check regulatory filings, which can run to hundreds of thousands of pages across multiple modules and jurisdictions. Generative tools can be trained on internal submission templates and past agency correspondence to ensure each required element is present, correctly referenced and consistent with the underlying data.
Some companies are experimenting with AI systems that scan a near‑final dossier for gaps or inconsistencies, flagging where a table doesn’t match a narrative, a reference is missing or a risk‑management section fails to address known safety signals. That kind of automated quality‑check, executives argue, can reduce the back‑and‑forth with regulators that often stretches out review timelines.
Regulators welcome efficiency but demand transparency
Regulatory agencies have signalled cautious openness to these tools, provided that human experts remain firmly in charge and companies can explain how AI outputs were generated and validated. Officials say they are less concerned with whether a draft text was written by a machine than with whether the data are accurate, the analysis is sound and accountability is clearly assigned.
That puts the onus on drugmakers to build governance frameworks around AI use: clear documentation of training data and model limitations, policies on where AI may or may not be used, and audit trails showing how key documents evolved from first draft to final submission. Cybersecurity and confidentiality are also high on the agenda, given that many generative models rely on cloud infrastructure and may be trained on sensitive clinical data if controls are lax.
Promise and risk as AI becomes part of the drug‑development fabric
Proponents argue that, done properly, AI could help level the playing field, allowing smaller biotech firms with lean teams to prepare high‑quality submissions and manage complex global trials that previously required Big Pharma‑scale resources. They also point to potential improvements in patient safety and trial diversity if AI‑driven analytics can spot emerging risks earlier or design studies that better reflect real‑world populations.
But the growing reliance on generative models in life‑and‑death contexts inevitably raises questions about bias, hallucinated content and over‑reliance on automated systems issues that the wider AI community is still grappling with. For now, drugmakers and regulators appear aligned on a cautious trajectory: push AI hard on the administrative and analytic grunt work, keep humans in the loop on judgement calls, and subject the entire process to the same scrutiny as the medicines themselves.
If that balance holds, the next generation of blockbuster therapies may owe as much to LLMs quietly drafting in the background as to the lab teams that first discovered the molecules speeding the journey from data to decision without loosening the guardrails that protect patients.